LAMISIL Safety Questions, LAMISIL Answers


More Here>>Side Effects - FDA Reports 2006-2008

Medications A-Z:   A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Welcome! Patientsville.com provides unique information about LAMISIL. Our extensive database of LAMISIL adverse events and LAMISIL warnings is updated regularly. If you have questions, you can post them to one of our health experts or ask others in our broad patient community.

>> Announcements
Check out our Hospital and Home Care Quality Reports.

Ask Our Health Experts about LAMISIL

Do You Have a Question about Your Health?

Our Doctors and Nurses will Help You Understand Your Symptoms and Feel Better!
Private, Confidential and Discreet




LAMISIL Safety Reports

Total LAMISIL reports: 579.
LAMISIL FDA safety alerts: 2001 .
Reported deaths: 14    Reported hospitalizations: 162.
Take LAMISIL Side Effects Survey or Share Your LAMISIL Story. LAMISIL Usage.

Showing 1-75 of 579 Next >

Physician from UNITED STATES reported LAMISIL problem on June 06, 2006. Male patient, 43 years of age, weighting 194.0 lb, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: acute hepatic failure, alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased, blood cholesterol increased, blood glucose increased, chromaturia, disability. LAMISIL dosage: 250 MG, QD, ORAL. During the same period patient was treated with ACTOS. Patient recovered.

LAMISIL problem was reported by a Physician from UNITED STATES on Mar 29, 2006. Male patient, 68 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: dermatitis, dermatitis psoriasiform, hyperhidrosis, oedema peripheral, skin lesion. LAMISIL dosage: 250 MG, QD, ORAL. During the same period patient was treated with LISINOPRIL, TRIAMTERENE, BENICAR, TOPROL, NORVASC, PRAVACHOL, ZETIA, ASPIRIN. Patient recovered.

Consumer or non-health professional from UNITED STATES reported LAMISIL problem on Mar 27, 2006. Female patient was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: arthralgia, urticaria. LAMISIL dosage: unknown. Patient recovered.

LAMISIL problem was reported by a Physician from UNITED STATES on Apr 19, 2006. Female patient was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: condition aggravated, systemic lupus erythematosus. LAMISIL dosage: unknown. Patient recovered.

Consumer or non-health professional from UNITED STATES reported LAMISIL problem on Mar 31, 2006. Female patient was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: hypersensitivity, pruritus, urticaria. LAMISIL dosage: unknown. Patient recovered.

LAMISIL problem was reported by a Consumer or non-health professional from UNITED STATES on Dec 15, 2005. Female patient was diagnosed with tinea pedis and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: disease recurrence, rash, skin exfoliation. LAMISIL dosage: unknown. Patient was hospitalized. Patient recovered.

Consumer or non-health professional from UNITED STATES reported LAMISIL problem on Jan 03, 2006. Female patient was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: alopecia, onychoclasis, rash, swelling. LAMISIL dosage: unknown. Patient recovered.

LAMISIL problem was reported by a Physician from UNITED STATES on Feb 17, 2006. Male patient, 73 years of age, was diagnosed with tinea pedis and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: erythema, oedema peripheral, pain, skin burning sensation, skin oedema, toxic epidermal necrolysis. LAMISIL dosage: 250 MG, QD, ORAL. During the same period patient was treated with DOXAZOSIN, ENALAPRIL MALEATE, METFORMIN, ALLOPURINOL. Patient recovered.

Physician from UNITED STATES reported LAMISIL problem on Jan 27, 2006. Female patient was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: cholestasis, jaundice, liver function test abnormal. LAMISIL dosage: 250 MG, QD, ORAL. Patient was hospitalized. Patient recovered.

LAMISIL problem was reported by a Physician from UNITED STATES on Feb 10, 2006. Male patient was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: hepatic failure. LAMISIL dosage: 250 MG, QD, ORAL. Patient recovered.

Physician from UNITED STATES reported LAMISIL problem on Feb 16, 2006. Male patient, 46 years of age, weighting 222.9 lb, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, blood lactate dehydrogenase increased, hepatic enzyme increased. LAMISIL dosage: 250 MG, QD, ORAL. Patient recovered.

LAMISIL problem was reported by a Physician from UNITED STATES on Feb 09, 2006. Male patient, 70 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: stevens-johnson syndrome. LAMISIL dosage: 250 MG, QD, ORAL. Patient was hospitalized. Patient recovered.

Physician from UNITED STATES reported LAMISIL problem on Feb 13, 2006. Female patient, 44 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: ageusia. LAMISIL dosage: 250 MG, QD, ORAL. Patient recovered.

LAMISIL problem was reported by a Physician from UNITED STATES on Sept 01, 2006. Female patient, 41 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: angioedema, urticaria. LAMISIL dosage: unknown. Patient was hospitalized. Patient recovered.

Consumer or non-health professional from UNITED STATES reported LAMISIL problem on Mar 17, 2006. Male patient, 56 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: pruritus, rash erythematous, skin exfoliation, skin fissures. LAMISIL dosage: 250 MG, QD, ORAL. Patient recovered.

LAMISIL problem was reported by a Consumer or non-health professional from UNITED STATES on June 16, 2006. Male patient was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: pruritus, urticaria. LAMISIL dosage: unknown. Patient recovered.

Physician from UNITED STATES reported LAMISIL problem on June 07, 2006. Male patient, 68 years of age, weighting 213.0 lb, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: oral discomfort, rash, skin exfoliation, stevens-johnson syndrome. LAMISIL dosage: 250 MG, QD, ORAL. During the same period patient was treated with KETEK, AVANDIA, LISINOPRIL, LIPITOR, LIMBITROL. Patient recovered.

LAMISIL problem was reported by a Physician from UNITED STATES on July 11, 2006. Female patient, 54 years of age, weighting 110.0 lb, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: ageusia, decreased appetite, dysgeusia, nausea, weight decreased. LAMISIL dosage: 250 MG, QD, ORAL. During the same period patient was treated with OPIUM ALKALOIDS AND DERIVATIVES, SYNTHROID. Patient recovered.

Health Professional from UNITED STATES reported LAMISIL problem on Aug 11, 2006. Female patient, 32 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: dermatitis allergic, pyrexia, rash, skin disorder, skin exfoliation, skin haemorrhage, skin lesion, stevens-johnson syndrome, toxic epidermal necrolysis. LAMISIL dosage: 250 MG, ORAL. Patient was hospitalized. Patient recovered.

LAMISIL problem was reported by a Physician from UNITED STATES on June 21, 2006. Female patient was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: ageusia. LAMISIL dosage: 250 MG, QD, ORAL. Patient recovered.

Physician from UNITED STATES reported LAMISIL problem on June 15, 2006. Female patient, 64 years of age, was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: arthralgia, rash. LAMISIL dosage: 250 MG, QD, ORAL. Patient recovered.

LAMISIL problem was reported by a Consumer or non-health professional from UNITED STATES on June 16, 2006. Female patient, 33 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: pruritus, rash papular, scar, skin discolouration, skin reaction, skin warm. LAMISIL dosage: 250 MG, QD, ORAL. Patient recovered.

Physician from UNITED STATES reported LAMISIL problem on June 27, 2006. Female patient was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: dysgeusia, visual disturbance. LAMISIL dosage: 250 MG, QD,ORAL. Patient recovered.

LAMISIL problem was reported by a Physician from UNITED STATES on June 30, 2006. Male patient, 56 years of age, weighting 190.0 lb, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: chills, diarrhoea, fatigue, myalgia, nausea, neutropenia, neutrophil percentage decreased, pyrexia, white blood cell count decreased. LAMISIL dosage: 250 MG, QD, ORAL. During the same period patient was treated with PRILOSEC. Patient recovered.

Consumer or non-health professional from UNITED STATES reported LAMISIL problem on July 09, 2006. Male patient, 17 years of age, was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: stevens-johnson syndrome. LAMISIL dosage: unknown. Patient recovered.

LAMISIL problem was reported by a Health Professional from UNITED STATES on Aug 25, 2006. Female patient, 72 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: dyspnoea, swelling face. LAMISIL dosage: 250 MG, QD, ORAL. During the same period patient was treated with CARDIZEM, DYAZIDE. Patient recovered.

Physician from UNITED STATES reported LAMISIL problem on Aug 02, 2006. Female patient was diagnosed with fungal skin infection and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: petechiae, platelet count decreased, rash. LAMISIL dosage: 250 MG, QD, ORAL. Patient recovered.

LAMISIL problem was reported by a Physician from UNITED STATES on Sept 27, 2006. Female patient, 57 years of age, weighting 119.0 lb, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: alopecia totalis, alopecia universalis. LAMISIL dosage: 250 MG, QD, ORAL. During the same period patient was treated with LANTUS, HUMALOG, EVISTA, CALCIUM, VITAMIN B, VITAMIN E, NAPROXEN. Patient recovered.

Consumer or non-health professional from UNITED STATES reported LAMISIL problem on Aug 07, 2006. Female patient, 69 years of age, weighting 140.0 lb, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: ageusia, nausea, weight decreased. LAMISIL dosage: 250 MG, QD, ORAL. Patient recovered.

LAMISIL problem was reported by a Consumer or non-health professional from UNITED STATES on Oct 04, 2005. Female patient, 29 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: urticaria. LAMISIL dosage: 250 MG, QD, ORAL. Patient recovered.

Consumer or non-health professional from UNITED STATES reported LAMISIL problem on Oct 04, 2005. Female patient, 32 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: urticaria. LAMISIL dosage: 250 MG, QD, ORAL. Patient recovered.

LAMISIL problem was reported by a Consumer or non-health professional from UNITED STATES on Oct 19, 2005. Female patient was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: headache, hypersensitivity, hypokinesia, myalgia, pain, pruritus, urticaria. LAMISIL dosage: unknown. Patient recovered.

Physician from UNITED STATES reported LAMISIL problem on Dec 02, 2005. Female patient, 29 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: pruritus, urticaria. LAMISIL dosage: 250 MG, ORAL. Patient recovered.

LAMISIL problem was reported by a Consumer or non-health professional from UNITED STATES on Oct 20, 2006. Female patient, 29 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: pruritus, rash papular, skin exfoliation. LAMISIL dosage: 250 MG, QD, ORAL. Patient recovered.

Consumer or non-health professional from UNITED STATES reported LAMISIL problem on Nov 20, 2006. Male patient was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: hepatocellular damage. LAMISIL dosage: unknown. Patient recovered.

LAMISIL problem was reported by a Consumer or non-health professional from UNITED STATES on Nov 22, 2005. Female patient, 37 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: erythema, hypersensitivity, urticaria. LAMISIL dosage: 250 MG, QD, ORAL. Patient recovered.

Consumer or non-health professional from UNITED STATES reported LAMISIL problem on Nov 30, 2005. Female patient, 78 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: biopsy skin, nail tinea, otorrhoea, overdose, pruritus, rash papular, skin discolouration, skin exfoliation. LAMISIL dosage: 250 MG, QD, ORAL. During the same period patient was treated with SINGULAIR, LISINOPRIL, AMITRIPTYLINE. Patient recovered.

LAMISIL problem was reported by a Physician from UNITED STATES on Dec 02, 2005. Female patient was diagnosed with nail tinea, ear infection and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: ear infection, hypersensitivity. LAMISIL dosage: 250 MG, QD, ORAL. During the same period patient was treated with ANTIBIOTICS. Patient was hospitalized. Patient recovered.

Health Professional from UNITED STATES reported LAMISIL problem on Aug 25, 2006. Male patient, 39 years of age, was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: rash. LAMISIL dosage: unknown. During the same period patient was treated with TYLENOL. Patient recovered.

LAMISIL problem was reported by a Physician from UNITED STATES on Aug 30, 2006. Female patient, 59 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: decreased appetite, diarrhoea, dysgeusia, nausea, vomiting, weight decreased. LAMISIL dosage: 250 MG QD ORAL. During the same period patient was treated with ARIMIDEX, BELLAMINE S, SYNTHROID, TOPROL, MICARDIS HCT. Patient recovered.

Consumer or non-health professional from UNITED STATES reported LAMISIL problem on Aug 31, 2006. Male patient was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: hypersensitivity, swelling face. LAMISIL dosage: unknown. Patient recovered.

LAMISIL problem was reported by a Pharmacist from UNITED STATES on Oct 02, 2006. Female patient, 43 years of age, weighting 119.9 lb, was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: anaphylactic reaction, arthralgia, arthritis. LAMISIL dosage: unknown. During the same period patient was treated with SYNTHROID, CONTRACEPTIVES UNS. Patient was hospitalized. Patient recovered.

Physician from UNITED STATES reported LAMISIL problem on Sept 27, 2006. Female patient, 36 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: ageusia, urticaria. LAMISIL dosage: 250 MG QD ORAL. Patient recovered.

LAMISIL problem was reported by a Consumer or non-health professional from UNITED STATES on Sept 28, 2006. Male patient, 69 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: blood bilirubin increased, dysgeusia, tongue coated, weight decreased. LAMISIL dosage: 250 MG QD ORAL. Patient recovered.

Physician from UNITED STATES reported LAMISIL problem on Jan 13, 2006. Female patient, 40 years of age, weighting 130.1 lb, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: ageusia, anorexia, asthenia, dysgeusia, pain in extremity, stress, tongue dry, weight decreased. LAMISIL dosage: unknown. Patient was hospitalized. Patient recovered.

LAMISIL problem was reported by a Physician from UNITED STATES on Oct 07, 2005. Male patient, 33 years of age, was diagnosed with body tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: aspartate aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased, chromaturia, hepatic enzyme increased, jaundice, ocular icterus. LAMISIL dosage: 250 MG QD ORAL. During the same period patient was treated with BACTRIM DS, PREDNISONE. Patient recovered.

Physician from UNITED STATES reported LAMISIL problem on Nov 03, 2005. Female patient, 67 years of age, was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: ageusia, appetite disorder, dysgeusia, leukopenia, neutropenia. LAMISIL dosage: 250 MG ORAL. During the same period patient was treated with CRESTOR, ACTONEL, EVISTA, SYNTHROID. Patient recovered.

LAMISIL problem was reported by a Physician from UNITED STATES on Nov 23, 2005. Female patient, 58 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: antinuclear antibody positive, cutaneous lupus erythematosus, erythema annulare, pruritus, rash, skin exfoliation, thermal burn. LAMISIL dosage: 250 MG QD ORAL. During the same period patient was treated with PREMARIN. Patient recovered.

Physician from UNITED STATES reported LAMISIL problem on Nov 28, 2005. Female patient, 36 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: erythema, erythema multiforme, pruritus, rash erythematous, skin exfoliation, skin reaction. LAMISIL dosage: 250 MG QD ORAL. Patient recovered.

LAMISIL problem was reported by a Physician from UNITED STATES on Oct 25, 2006. Female patient, 53 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: hypersensitivity, pruritus, rash erythematous. LAMISIL dosage: 250 MG QD ORAL. During the same period patient was treated with SYNTHROID, ALPRAZOLAM, QUESTRAN LIGHT. Patient recovered.

Physician from UNITED STATES reported LAMISIL problem on Nov 03, 2005. Male patient, 59 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased, chromaturia, hepatitis toxic, pyrexia. LAMISIL dosage: 250 MG QD ORAL. Patient recovered.

LAMISIL problem was reported by a Physician from UNITED STATES on Sept 30, 2005. Male patient, 70 years of age, weighting 224.0 lb, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: pruritus, rash erythematous. LAMISIL dosage: 250 MG QD ORAL. During the same period patient was treated with CYMBALTA, XANAX, VIAGRA. Patient recovered.

Physician from UNITED STATES reported LAMISIL problem on Oct 04, 2005. Female patient, 13 years of age, weighting 110.0 lb, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: rash papular. LAMISIL dosage: 250 MG QD ORAL. Patient recovered.

LAMISIL problem was reported by a Consumer or non-health professional from UNITED STATES on Aug 11, 2006. Female patient was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: exfoliative rash, hypersensitivity, rash papular. LAMISIL dosage: unknown. Patient recovered.

Consumer or non-health professional from UNITED STATES reported LAMISIL problem on Aug 18, 2006. Female patient, 53 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: ageusia, weight decreased. LAMISIL dosage: 250 MG QD ORAL. Patient recovered.

LAMISIL problem was reported by a Consumer or non-health professional from UNITED STATES on Aug 28, 2006. Male patient, 26 years of age, was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: hepatocellular damage. LAMISIL dosage: unknown. Patient recovered.

Physician from UNITED STATES reported LAMISIL problem on Apr 13, 2006. Female patient, 37 years of age, was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, aspartate aminotransferase increased, hepatic enzyme increased, jaundice. LAMISIL dosage: unknown. During the same period patient was treated with SEPTRA DS. Patient recovered.

LAMISIL problem was reported by a Consumer or non-health professional from UNITED STATES on Aug 15, 2006. Female patient, 60 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: hypersensitivity, rash. LAMISIL dosage: unknown. Patient recovered.

Physician from UNITED STATES reported LAMISIL problem on May 05, 2006. Male patient, 59 years of age, weighting 179.9 lb, was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: skin exfoliation, skin lesion. LAMISIL dosage: 250 MG, QD, ORAL. Patient recovered.

LAMISIL problem was reported by a Consumer or non-health professional from UNITED STATES on May 05, 2006. Female patient, 36 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: cough, pruritus, rash, stridor, urticaria, wheezing. LAMISIL dosage: 250 MG, QD, ORAL. Patient was hospitalized. Patient recovered.

Consumer or non-health professional from UNITED STATES reported LAMISIL problem on July 31, 2006. Female patient was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: discomfort. LAMISIL dosage: unknown. Patient recovered.

LAMISIL problem was reported by a Health Professional from UNITED STATES on May 11, 2006. Female patient, 56 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: systemic lupus erythematosus rash. LAMISIL dosage: 250 MG, QD, ORAL. Patient recovered.

Consumer or non-health professional from UNITED STATES reported LAMISIL problem on May 18, 2006. Female patient, 47 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: chromaturia, decreased appetite, dysgeusia, insomnia, jaundice, laboratory test abnormal, ocular icterus, pruritus. LAMISIL dosage: 250 MG, QD, ORAL. Patient recovered.

LAMISIL problem was reported by a Physician from UNITED STATES on Sept 06, 2006. Female patient, 52 years of age, weighting 198.0 lb, was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: face oedema, pain, periorbital oedema, pruritus, swelling face, urticaria. LAMISIL dosage: unknown. During the same period patient was treated with PREMPRO. Patient recovered.

Physician from UNITED STATES reported LAMISIL problem on June 27, 2006. Female patient, 60 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: oedema peripheral, skin exfoliation, skin reaction. LAMISIL dosage: 250 MG, QD, ORAL. Patient was hospitalized. Patient recovered.

LAMISIL problem was reported by a Consumer or non-health professional from UNITED STATES on May 25, 2006. Female patient, 37 years of age, was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: pruritus. LAMISIL dosage: unknown. Patient recovered.

Physician from JAPAN reported LAMISIL problem on Feb 16, 2007. Female patient, 70 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: aldolase increased, back pain, myalgia. LAMISIL dosage: unknown. Patient recovered.

LAMISIL problem was reported by a Consumer or non-health professional from UNITED STATES on Feb 19, 2007. Female patient, child 8 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: bone marrow disorder, white blood cell count decreased. LAMISIL dosage: 250 MG, QD. Patient recovered.

Physician from JAPAN reported LAMISIL problem on Feb 19, 2007. Female patient, 86 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: eosinophil count increased, haematocrit decreased, haematology test abnormal, haemoglobin decreased, lymphocyte count decreased, monocyte count decreased, red blood cell count decreased. LAMISIL dosage: unknown. During the same period patient was treated with WARFARIN, OMEPRAL, LASIX, FLUITRAN, ALLOPURINOL, ONEALFA, MUCOSTA, JUVELA. Patient recovered.

LAMISIL problem was reported by a Consumer or non-health professional from VENEZUELA on Feb 22, 2007. Male patient, 66 years of age, was diagnosed with nail tinea, fungal skin infection and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: abdominal discomfort, hypertension, somnolence. LAMISIL dosage: unknown. During the same period patient was treated with GLUCOVANCE, TRENTAL, PRETERAX, CONCOR, TELMISARTAN, SOMESE. Patient recovered.

Physician from FRANCE reported LAMISIL problem on Feb 23, 2007. Male patient, 40 years of age, was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: pyrexia. LAMISIL dosage: unknown. Patient recovered.

LAMISIL problem was reported by a Physician from FRANCE on Feb 23, 2007. Female patient, 70 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: purpura, rash macular, rash papular. LAMISIL dosage: unknown. Patient recovered.

Consumer or non-health professional from CHINA reported LAMISIL problem on Feb 27, 2007. Female patient, 32 years of age, was diagnosed with nail tinea and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: abdominal pain upper, genital discharge. LAMISIL dosage: 250 MG, QD. Patient was hospitalized. Patient recovered.

LAMISIL problem was reported by a Physician from UNITED STATES on Feb 26, 2007. Male patient, weighting 150.0 lb, was diagnosed with onychomycosis and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: blood potassium increased, dysgeusia, hypogeusia, nausea, oral intake reduced, weight decreased. LAMISIL dosage: 250 MG, QD. During the same period patient was treated with SYNTHROID, LIPITOR, METOPROLOL SUCCINATE. Patient recovered.

Pharmacist from UNITED STATES reported LAMISIL problem on Feb 26, 2007. Male patient, 73 years of age, was diagnosed with onychomycosis and was treated with LAMISIL. After drug was administered, patient experienced the following problems/side effects: blood iron decreased, melaena. LAMISIL dosage: 250 MG, QD. During the same period patient was treated with CARAFATE. Patient recovered.

Showing 1-75 of 579 Next >

Ask Our Patient Community about LAMISIL

Select a Medication and Click to Access Reports about Side Effects and Adverse Reactions

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

This drug has as active FDA Safety Alert This drug has an active FDA Safety Alert
A
Abacavir sulfate
Abatacept
Abilify
Acamprosate calcium
AccuprilThis drug has as active FDA Safety Alert
AccutaneThis drug has as active FDA Safety Alert
AceonThis drug has as active FDA Safety Alert
Aciphex
Actiq (fentanyl citrate)
ActimmuneThis drug has as active FDA Safety Alert
(aripiprazole) (quinapril) (isotretinoin) (perindopril) (rabeprazole) (interferon gamma-1b)
ActonelThis drug has as active FDA Safety Alert (risedronate)
Actoplus MetThis drug has as active FDA Safety Alert (pioglitazone)
ActosThis drug has as active FDA Safety Alert (pioglitazone)
AcuTect (technetium Tc 99m apcitide)
Adefovir dipivoxil
Advair Diskus(Fluticasone propionate; Salmeterol xinafoate)
AdderallThis drug has as active FDA Safety Alert (amphetamine salts)
Agenerase (amprenavir)
Aggrastat (tirofiban)
Alamast (pemirolast)
AlendronateThis drug has as active FDA Safety Alert
AlemtuzumabThis drug has as active FDA Safety Alert
AleveThis drug has as active FDA Safety Alert (naproxen sodium)
Alfuzosin
Alinia (nitazoxanide)
Alimta (pemetrexed)
Alitretinoin
Almotriptan malateThis drug has as active FDA Safety Alert
Alosetron hydrochloride
Aloxi (palonosetron)
Alrex (loteprednol etabonate)
AltaceThis drug has as active FDA Safety Alert (ramipril)
Ambien (zolpidem tartrate)
AmergeThis drug has as active FDA Safety Alert (naratriptan)
Aminolevulinic acid
AmiodaroneThis drug has as active FDA Safety Alert
Amitiza (lubiprostone)
AmnesteemThis drug has as active FDA Safety Alert (isotretinoin)
Amphadase (hyaluronidase)
luronidase)
Amphetamine saltsThis drug has as active FDA Safety Alert
Amprenavir
AnaproxThis drug has as active FDA Safety Alert (naproxen sodium)
Angiomax (bivalirudin)
Anidulafungin
Antagon (ganirelix acetate)
Anthelios SX (avobenzone, ecamsule, octocrylene)
Apidra (insulin glulisine recombinant)
Apokyn (apomorphine)
Aprepitant
Aprotinin
Aptivus (tipranavir)
AranespThis drug has as active FDA Safety Alert (darbepoetin alpha)
Arava (leflunomide)
Arformoterol

Argatroban
ArediaThis drug has as active FDA Safety Alert (pamidronate)
Aripiprazole
Arixtra (fondaparinux)
Aromasin (exemestane)
Arranon (nelarabine)
Arsenic trioxide
Aspirin
Atacand (candesartan cilexetil)
Atazanavir sulfate
AtomoxetineThis drug has as active FDA Safety Alert
Avastin (bevacizumab)
Avelox (moxifloxacin)
Avobenzone, Ecamsule, Octocrylene
Avodart (dutasteride)
Avonex (interferon beta-1a)
AxertThis drug has as active FDA Safety Alert (almotriptan malate)
Azacitidine
Azilect (rasagiline)
Azopt (brinzolamide)

back to top

B
Balsalazide disodium
Baraclude (entecavir)
BenazeprilThis drug has as active FDA Safety Alert
Benicar (olmesartan medoxomil)
Bevacizumab
Bexarotene
BextraThis drug has as active FDA Safety Alert (valdecoxib)
BiaxinThis drug has as active FDA Safety Alert (clarithromycin)
Bimatoprost
Bivalirudin
BonivaThis drug has as active FDA Safety Alert (ibandronate)
Bortezomib
Brinzolamide
Brovana (arformoterol)
BupropionThis drug has as active FDA Safety Alert
Butisol sodium
Byetta (exenatide)


back to top

C
Calfactant
CampathThis drug has as active FDA Safety Alert (alemtuzumab)
Campral (acamprosate calcium)
Cancidas (caspofungin)
Candesartan cilexetil
Capecitabine
CapotenThis drug has as active FDA Safety Alert (captopril)
CaptoprilThis drug has as active FDA Safety Alert
CarbamazepineThis drug has as active FDA Safety Alert
CarbatrolThis drug has as active FDA Safety Alert (carbamazepine)
Carbrital (pentobarbital and carbromal)
Caspofungin
Cefditoren pivoxil
CefepimeThis drug has as active FDA Safety Alert
CeftriaxoneThis drug has as active FDA Safety Alert
CelebrexThis drug has as active FDA Safety Alert (celecoxib)
CelecoxibThis drug has as active FDA Safety Alert
CelexaThis drug has as active FDA Safety Alert (citalopram hydrobromide)
Cetrorelix acetate
Cetrotide (cetrorelix acetate)
Cetuximab
Cevimeline
ChantixThis drug has as active FDA Safety Alert (varenicline)
Cialis (tadalafil)
Cilostazol
Cinacalcet
Cirlesonide
CitalopramThis drug has as active FDA Safety Alert
ClaravisThis drug has as active FDA Safety Alert (isotretinoin)
ClarithromycinThis drug has as active FDA Safety Alert
Clarinex (desloratadine)
Clolar (clofarabine)
Clofarabine
Clozapine
Clozaril (clozapine)
CodeineThis drug has as active FDA Safety Alert
Colazal (balsalazide disodium)
Colesevelam
ColistimethateThis drug has as active FDA Safety Alert
Coly-Mycin M (colistimethate)This drug has as active FDA Safety Alert
Comtan (entacapone)
Concerta (methylphenidate)
Conivaptan
CordaroneThis drug has as active FDA Safety Alert (amiodarone)
CrestorThis drug has as active FDA Safety Alert (rosuvastatin calcium)
Cubicin (daptomycin)
Curosurf (poractant alfa)
CylertThis drug has as active FDA Safety Alert (pemoline)
CymbaltaThis drug has as active FDA Safety Alert (duloxetine)
CytotecThis drug has as active FDA Safety Alert (misoprostol)

back to top

D
Dacogen (decitabine)
Dalfopristin
Dalmane (flurazepam)
Daptomycin
Darbepoetin alphaThis drug has as active FDA Safety Alert
Darifenacin
Darunavir
Dasatinib
Daytrana (methylphenidate transdermal)
DDAVPThis drug has as active FDA Safety Alert (desmopressin)
DDAVP Nasal SprayThis drug has as active FDA Safety Alert (demopressin)
DDAVP Rhinal TubeThis drug has as active FDA Safety Alert (desmopressin)
DDVPThis drug has as active FDA Safety Alert (desmopressin
Decitabine
Deferasirox
Definity (perflutren lipid microspheres)
DepaconThis drug has as active FDA Safety Alert (valproate)
DepakeneThis drug has as active FDA Safety Alert (valproate)
DepakoteThis drug has as active FDA Safety Alert (valproate)
Desloratadine
DesmopressinThis drug has as active FDA Safety Alert
Detrol (tolterodine tartrate)
terodine tartrate)
Dexedrine (dextroamphetamine sulfate)
Dexmedetomidine
Dexmethylphenidate HCl
> Dextroamphetamine sulfate
Diastat AcuDialThis drug has as active FDA Safety Alert
Diazepam rectal gelThis drug has as active FDA Safety Alert
DidronelThis drug has as active FDA Safety Alert (etidronate)
DiprivanThis drug has as active FDA Safety Alert (propofol)
Dofetilide
Doral (quazepam)
Doxercalcif
Drospirenone
DuloxetineThis drug has as active FDA Safety Alert
DuragesicThis drug has as active FDA Safety Alert (fentanyl transdermal system)
Dutasteride

back to top

E

Eculizumab
Edetate disodium
Efalizumab
Efavirenz
EffexorThis drug has as active FDA Safety Alert (venlafaxine)
Elestat (epinastine)
EletriptanThis drug has as active FDA Safety Alert
Elidel (pimecrolimus)
Ellence (epirubicin)
Eloxatin (oxaliplatin)
Emend (aprepitant)
Emtricitabine
Emtriva (emtricitabine)
Enablex (darifenacin)
Enalapril / EnalaprilatThis drug has as active FDA Safety Alert
Endrate (edetate disodium)
Enfuvirtide
Entacapone
Entecavir
Epinastine
Epirubicin
Eplerenone
Epoetin alfaThis drug has as active FDA Safety Alert
EpogenThis drug has as active FDA Safety Alert (epoetin alfa)
Eptifibatide
EquetroThis drug has as active FDA Safety Alert (carbamazepine)
Eraxis (anidulafungin)
Erbitux (cetuximab)
Ertaczo (sertaconazole)
EscitalopramThis drug has as active FDA Safety Alert
Estazolam
Eszopiclone
Ethchlorvynol

Ethinyl estradiol
EtidronateThis drug has as active FDA Safety Alert
Evoxac (cevimeline)
Exelon (rivastigmine tartrate)
Exenatide
Exjade (deferasirox)
Exemestane
Extraneal (icodextrin)
Ezetimibe
Ezetimibe/simvastatin

back to top

F
Factive (gemifloxacin mesylate)
Faslodex (fulvestrant)
FelbamateThis drug has as active FDA Safety Alert
FelbatolThis drug has as active FDA Safety Alert (felbamate)
Fentanyl buccal tabletsThis drug has as active FDA Safety Alert
Fentanyl citrate
Fentanyl transdermal systemThis drug has as active FDA Safety Alert
FentoraThis drug has as active FDA Safety Alert (fentanyl buccal tablets)
Ferrlecit (sodium ferric gluconate complex)
Fleet Accu-PrepThis drug has as active FDA Safety Alert (sodium phosphate)
Fleet Phospho-SodaThis drug has as active FDA Safety Alert (sodium phosphate)
FluoxetineThis drug has as active FDA Safety Alert
Flurazepam
Fluticasone propionate
FluvoxamineThis drug has as active FDA Safety Alert
Focalin (dexmethylphenidate)
Focalin XR (dexmethylphenidate)
Fomivirsen
Fondaparinux
Foradil (formoterol fumarate)
Formoterol fumarate
FosamaxThis drug has as active FDA Safety Alert (alendronate)
FosinoprilThis drug has as active FDA Safety Alert
FrovaThis drug has as active FDA Safety Alert (frovatriptan succinate)
Frovatriptan succinateThis drug has as active FDA Safety Alert
Fulvestrant
Fuzeon (enfuvirtide)

G
GabapentinThis drug has as active FDA Safety Alert
GabitrilThis drug has as active FDA Safety Alert (tiagabine)
Gadobenate DimeglumineThis drug has as active FDA Safety Alert
GadodiamideThis drug has as active FDA Safety Alert
GadoliniumThis drug has as active FDA Safety Alert
Gadopentetate DimeglumineThis drug has as active FDA Safety Alert
GadoteridolThis drug has as active FDA Safety Alert
GadoversetamideThis drug has as active FDA Safety Alert
GalantamineThis drug has as active FDA Safety Alert
Ganirelix acetate
GatifloxacinThis drug has as active FDA Safety Alert
GefitinibThis drug has as active FDA Safety Alert
Gemifloxacin mesylate
Gemtuzumab ozogamicin
Geodon (ziprasidone)
Gleevec (imatinib mesylate)

back to top

H
Halcion (triazolam)
HaldolThis drug has as active FDA Safety Alert (haloperidol)
Haloperidol
This drug has as active FDA Safety Alert
Hectorol (doxercalcif)
Hepsera (adefovir dipivoxil)
Hyaluronidase
Hydase (hyaluronidase)
Human Secretin

back to top

I
IbandronateThis drug has as active FDA Safety Alert
Ibuprofen
Icodextrin
Iloprost
Imatinib mesylate
Increlex (Mecasermin [rDNA origin]
Infasurf Preservative Free (calfactant)
ImitrexThis drug has as active FDA Safety Alert (sumatriptan)
Innohep (tinzaparin)
Inspra (eplerenone)
Insulin Aspart recombinant
Insulin Detemir recombinant
Insulin Glargine recombinant

Insulin Glulisine recombinant

Intron A (interferon alfa-2b)
Integrilin (eptifibatide)
ifibatide)
Interferon alfa-2b
Interferon beta-1a
Interferon gamma-1bThis drug has as active FDA Safety Alert
Invega (paliperidone)
Iplex  (mecasermin rinfabate)
IressaThis drug has as active FDA Safety Alert (gefitinib)
IsotretinoinThis drug has as active FDA Safety Alert

back to top

J
Januvia (sitagliptin phosphate)

back to top

K
Kaletra (lopinavir; ritonavir)
Kepivance (palifermin)
KeppraThis drug has as active FDA Safety Alert (levetiracetam)
Ketek (telithromycin)
Ketotifen fumarate

back to top

L
LamictalThis drug has as active FDA Safety Alert (lamotrigine)
LamotrigineThis drug has as active FDA Safety Alert
Lantus (insulin glargine recombinant)
Leflunomide
Lenalidomide
Lepirudin recombinant
Levalbuterol
Levemir (insulin detemir recombinant)
LevetiracetamThis drug has as active FDA Safety Alert
Levitra (vardenafil)
Levonorgestrel
Levothyroxine sodium
Levulan Kerastick (aminolevulinic acid)
LexaproThis drug has as active FDA Safety Alert (escitalopram)
Lindane
Linezolid
This drug has as active FDA Safety Alert
LisinoprilThis drug has as active FDA Safety Alert
Lopinavir/ritonavir
Lotemax (loteprednol etabonate)
LotensinThis drug has as active FDA Safety Alert (benazepril)
Loteprednol etabonate
Lotronex (alosetron hydrochloride)
Lubiprostone
Lucentis (ranibizumab)
Lumigan (bimatoprost)
Lunestra (eszopiclone)
LyricaThis drug has as active FDA Safety Alert (pregabalin)

back to top

M
Macugen (pegaptanib)
MagnevistThis drug has as active FDA Safety Alert (gadopentetate dimeglumine)
Maraviroc
MavikThis drug has as active FDA Safety Alert (trandolapril)
MaxaltThis drug has as active FDA Safety Alert (rizatriptan benzoate)
MaxipimeThis drug has as active FDA Safety Alert (cefepime)
Mecasermin [rDNA origin]
Mecasermin-rinfabate
Meloxicam
Memantine
Metadate CD (methylphenidate HCl)
ylphenidate HCl)
Methylphenidate HCl
Methylphenidate transdermal
Mequinol
Micafungin
Micardis (telmisartan)
misartan)
MifeprexThis drug has as active FDA Safety Alert (mifepristone)
MifepristoneThis drug has as active FDA Safety Alert
Miglustat
MinirinThis drug has as active FDA Safety Alert (desmopressin)
MirtazapineThis drug has as active FDA Safety Alert
MisoprostolThis drug has as active FDA Safety Alert
Mobic (meloxicam)
Modafinil
MoexiprilThis drug has as active FDA Safety Alert
MonoprilThis drug has as active FDA Safety Alert (fosinopril)
Moxifloxacin
MultiHanceThis drug has as active FDA Safety Alert (gadobenate dimeglumine)
Mycamine (micafungin)
Mylotarg (gemtuzumab ozogamicin)

back to top

N
Namenda (memantine)
NaprosynThis drug has as active FDA Safety Alert (naproxen)
NaproxenThis drug has as active FDA Safety Alert
Naratriptan
Nesiritide recombinant
Nateglinide
Natrecor (nesiritide recombinant)
NefazodoneThis drug has as active FDA Safety Alert
Nelarabine
NeoTect Kit (technetium Tc 99m depreotide)
Nesiritide recombinant
NeurontinThis drug has as active FDA Safety Alert (gabapentin)
Nexavar (sorafenib)
Nitazoxanide
Nitisinone
Norelgestromin
NovoLog (insulin aspart recombinant)
Noxafil (posaconazole)

back to top

O
Olanzapine
Olanzapine/fluoxetineThis drug has as active FDA Safety Alert
Olmesartan medoxomil
Omacor (omega-3-acid ethyl esters)
OmalizumabThis drug has as active FDA Safety Alert
Omega-3-acid ethyl esters
Omnaris (cirlesonide)
OmniscanThis drug has as active FDA Safety Alert (gadodiamide)
OptiMARK (gadoversetamide)
Optison (perflutren protein-type A microspheres)
Orencia (abatacept)
Orfadin (nitisinone)
Orlistat
Ortho Evra (norelgestromin; ethinyl estradiol)
Oseltamivir phosphate
OsmoprepThis drug has as active FDA Safety Alert (sodium phosphate)
Oxaliplatin
OxcarbazepineThis drug has as active FDA Safety Alert


back to top

P
PaceroneThis drug has as active FDA Safety Alert (amiodarone)
Palifermin
Paliperidone
PamidronateThis drug has as active FDA Safety Alert
Panitumumab
Panretin Gel (alitretinoin)
Pantoprazole
Paricalcitol
ParoxetineThis drug has as active FDA Safety Alert
PaxilThis drug has as active FDA Safety Alert (paroxetine)
Pegaptanib
Pegvisomant

Pemetrexed
PemolineThis drug has as active FDA Safety Alert
Pentobarbital and carbromal
Perflutren lipid microspheres
PerindoprilThis drug has as active FDA Safety Alert
PhenerganThis drug has as active FDA Safety Alert (promethazine)
Pimecrolimus

PioglitazoneThis drug has as active FDA Safety Alert
Placidyl (ethchlorvynol)
Plan B (levonorgestrel)
Pletal (cilostazol)
Poractant alfa
Posaconazole
Pramlintide Acetate
Precedex (dexmedetomidine)
PregabalinThis drug has as active FDA Safety Alert
Prezista (darunavir)
Prialt (ziconotide)
Priftin (rifapentine)
PrinivilThis drug has as active FDA Safety Alert (lisinopril)
ProcritThis drug has as active FDA Safety Alert (epoetin alfa)
ProHanceThis drug has as active FDA Safety Alert (gadoteridol)
PromethazineThis drug has as active FDA Safety Alert
PropofolThis drug has as active FDA Safety Alert
Prosom (estazolam)
Protonix (pantoprazole)
Protopic (tacrolimus)
Provigil (modafinil)
ProzacThis drug has as active FDA Safety Alert (fluoxetine)
Prussian blue


back to top

Q
Quazepam
Quetiapine

QuinaprilThis drug has as active FDA Safety Alert
Quinupristin

R
Rabeprazole
Radiogardase
(prussian blue)
Ramelteon
RamiprilThis drug has as active FDA Safety Alert
Ranexa (ranolazine)
Ranibizumab
Ranolazine
Rapamune (sirolimus)
Raptiva (efalizumab)
Rasagiline
RazadyneThis drug has as active FDA Safety Alert (galantamine)
Rebetol (ribavirin)
ReclastThis drug has as active FDA Safety Alert (zoledronic acid)
Refludan (lepirudin recombinant)
Relenza (zanamivir)
RelpaxThis drug has as active FDA Safety Alert (eletriptan)
RemeronThis drug has as active FDA Safety Alert (mirtazapine)